Impact of Automated Targeted Medication Review Electronic Alerts to Reduce Potentially Inappropriate Medication Prescribing Among Medicare Enrolled Patients With Dementia [0.03%]
自动化靶向药物审查电子预警系统减少痴呆症患者潜在不适当用药的效果研究
Armando Silva-Almodóvar,Andrea Malfara,Milap C Nahata
Armando Silva-Almodóvar
Background: Background:Finding ways to reduce prescribing of potentially inappropriate medications (PIMs) among patients with dementia is necessary. Objec...
Observational Study
The Annals of pharmacotherapy. 2020 Oct;54(10):967-974. DOI:10.1177/1060028020915790 2020
Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus [0.03%]
比较退伍军人2型糖尿病患者使用恩格列净和利拉鲁肽的体重结果
Ted Robert Grabarczyk,Natalie Koury Wissman
Ted Robert Grabarczyk
Background: Glucagon-like peptide-1 agonists and sodium glucose cotransporter 2 inhibitors are associated with weight loss and improved cardiovascular outcomes, and are increasingly used in pharmacotherapy for type 2 diab...
Observational Study
The Annals of pharmacotherapy. 2020 Oct;54(10):981-987. DOI:10.1177/1060028020915791 2020
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea [0.03%]
索利那新治疗嗜睡症和阻塞性睡眠呼吸暂停中的过度嗜睡效果如何？
Jason Powell,Chris Piszczatoski,Scott Garland
Jason Powell
Objective: The purpose of this article is to review the available clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol as well as its role in clinical practice. ...
Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy [0.03%]
口服基因疗法onasemnogene abeparvovec-xioi治疗脊髓性肌肉萎缩症
Debra Stevens,Melanie K Claborn,Brooke L Gildon et al.
Debra Stevens et al.
Objective: To review the efficacy and safety of onasemnogene abeparvovec-xioi (Zolgensma) in the treatment of spinal muscular atrophy (SMA). Data sources:...
Association Between Antipsychotics and Osteoporosis Based on Real-World Data [0.03%]
基于真实世界数据的抗精神病药物与骨质疏松症的关系
Satoshi Yokoyama,Shoki Wakamoto,Yuki Tanaka et al.
Satoshi Yokoyama et al.
Background: Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing ser...
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [0.03%]
尼拉帕利治疗复发性卵巢上皮癌、输卵管癌或原发性腹膜癌
Lloreta Kerliu,Samantha Myruski,Afeefa Bhatti et al.
Lloreta Kerliu et al.
Objective: To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC). ...
Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed [0.03%]
胃肠道出血住院后恢复使用直接口服抗凝剂的相关结局指标分析
Sara M Valanejad,Kyle A Davis,Sarah A Nisly
Sara M Valanejad
Background: Although direct oral anticoagulants (DOACs) carry a lower bleeding risk compared with warfarin, gastrointestinal bleeds (GIB) are a known complication. There are limited data observing outcomes associated with...
Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials [0.03%]
糖皮质激素治疗突发性耳聋疗效的系统评价和Meta分析：随机对照试验部分
Jinfei Li,Lei Ding
Jinfei Li
Background: The best way to administer steroids for sudden sensorineural hearing loss (SSHL) is still unclear. The present study was aimed at estimating the efficacy of steroids by intratympanic, systemic, and combined th...
Ethical, Economic, Societal, Clinical, and Pharmacology Uncertainties Associated With Milasen and Other Personalized Drugs [0.03%]
与Milasen及其他个性化药物相关的伦理、经济、社会、临床和药理学不确定性
Pedro Amariles,Juliana Madrigal-Cadavid
Pedro Amariles
Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials [0.03%]
卤倍他索丙酸酯和他扎罗汀联合治疗银屑病：II期和III期临床试验的综述研究
Vignesh Ramachandran,Brooke Bertus,Arjun M Bashyam et al.
Vignesh Ramachandran et al.
Objective: To review phase II and III clinical trial data to evaluate the efficacy and safety of the halobetasol propionate/tazarotene (HP/TAZ) combination lotion (Duobrii), a medication approved by the Food and Drug Administration in April...